Abstract
Introduction: There are no standard systemic therapies for the treatment of fibrolamellar carcinoma (FLC), as surgery remains the only definitive option. We share our experiences using systemic “triple therapy” (TT) with 5-fluorouracil, interferon, and nivolumab for the treatment of relapsed, refractory, metastatic, or unresectable FLC. Methods: Data from all patients who received TT from May 2018 to July 2020 were reviewed to assess response, survival, and toxicity. Results: A total of 22 patients were treated with TT, of which 14 (median age of 21 years) were evaluable. They received a median of 18 cycles (8–44). At the time of analysis, the median progression-free survival was 9 months (4.5–26), 29% longer than prior to TT, with 5 patients achieving clinical remission, 8 patients stable or improving, and 1 progression. Overall objective response (clinical remission + partial response) was 50% and tumor control rate (clinical remission + partial response + stable disease) was 93%. Two patients withdrew from treatment due to side effects. Discussion/Conclusion: Our early results support TT as a promising medical option to slow disease progression and prolong survival in high-risk patients with FLC. TT can be administered in the outpatient setting and has shown good tolerability. Further longitudinal data is needed to confirm outcomes, especially in patients still early in their treatment.
References
1.
El-Serag
HB
, Davila
JA
. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study
. Hepatology
. 2004
;39
(3
):798
–803
. .2.
Eggert
T
, McGlynn
KA
, Duffy
A
, Manns
MP
, Greten
TF
, Altekruse
SF
. Fibrolamellar hepatocellular carcinoma in the USA, 2000-2010: A detailed report on frequency, treatment and outcome based on the Surveillance, Epidemiology, and End Results database
. United European Gastroenterol J
. 2013
;1
(5
):351
–7
. .3.
Graham
RP
. Fibrolamellar carcinoma: What is new and why it matters
. Surg Pathol Clin
. 2018
;11
(2
):377
–87
. .4.
Lafaro
KJ
, Pawlik
TM
. Fibrolamellar hepatocellular carcinoma: current clinical perspectives
. J Hepatocell Carcinoma
. 2015
;2
:151
–7
. .5.
Sergi
CM
. Hepatocellular carcinoma, fibrolamellar variant: diagnostic pathologic criteria and molecular pathology update. A primer
. Diagnostics (Basel)
. 2015
;6
(1
):3
. .6.
Graham
RP
, Jin
L
, Knutson
DL
, Kloft-Nelson
SM
, Greipp
PT
, Waldburger
N
, et al. DNAJB1-PRKACA is specific for fibrolamellar carcinoma
. Mod Pathol
. 2015
;28
(6
):822
–9
. .7.
Chaudhari
VA
, Khobragade
K
, Bhandare
M
, Shrikhande
SV
. Management of fibrolamellar hepatocellular carcinoma
. Chin Clin Oncol
. 2018
;7
(5
):51
. .8.
Kaseb
AO
, Shama
M
, Sahin
IH
, Nooka
A
, Hassabo
HM
, Vauthey
JN
, et al. Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma
. Oncology
. 2013
;85
(4
):197
–203
. .9.
Torbenson
M
. Fibrolamellar carcinoma: 2012 update
. Scientifica (Cairo)
. 2012
;2012
:743790
–15
. .10.
Kassahun
WT
. Contemporary management of fibrolamellar hepatocellular carcinoma: diagnosis, treatment, outcome, prognostic factors, and recent developments
. World J Surg Oncol
. 2016
;14
(1
):151
. .11.
Fonseca
GM
, Varella
AD
, Coelho
FF
, Abe
ES
, Dumarco
RB
, Herman
P
. Downstaging and resection after neoadjuvant therapy for fibrolamellar hepatocellular carcinoma
. World J Gastrointest Surg
. 2014
;6
(6
):107
–11
. .12.
Patt
YZ
, Hassan
MM
, Lozano
RD
, Brown
TD
, Vauthey
JN
, Curley
SA
, et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon alfa-2b for treatment of hepatocellular carcinoma
. J Clin Oncol
. 2003
;21
(3
):421
–7
. .13.
Maniaci
V
, Davidson
BR
, Rolles
K
, Dhillon
AP
, Hackshaw
A
, Begent
RH
, et al. Fibrolamellar hepatocellular carcinoma: prolonged survival with multimodality therapy
. Eur J Surg Oncol
. 2009
;35
(6
):617
–21
. .14.
Kim
AK
, Gani
F
, Layman
AJ
, Besharati
S
, Zhu
Q
, Succaria
F
, et al. Multiple immune-suppressive mechanisms in fibrolamellar carcinoma
. Cancer Immunol Res
. 2019
;7
(5
):805
–12
. .15.
Hou
A
, Hou
K
, Huang
Q
, Lei
Y
, Chen
W
. Targeting myeloid-derived suppressor cell, a promising strategy to overcome resistance to immune checkpoint inhibitors
. Front Immunol
. 2020
;11
:783
. .16.
Guo
L
, Zhang
H
, Chen
B
. Nivolumab as programmed death-1 (PD-1) inhibitor for targeted immunotherapy in tumor
. J Cancer
. 2017
;8
(3
):410
–6
. .17.
Qin
W
, Hu
L
, Zhang
X
, Jiang
S
, Li
J
, Zhang
Z
, et al. The diverse function of PD-1/PD-L pathway beyond cancer
. Front Immunol
. 2019
;10
:2298
. .18.
Brahmer
JR
, Hammers
H
, Lipson
EJ
. Nivolumab: targeting PD-1 to bolster antitumor immunity
. Future Oncol
. 2015
;11
(9
):1307
–26
. .19.
Nouso
K
. Current chemotherapies for advanced hepatocellular carcinoma
. Clin J Gastroenterol
. 2013
;6
(2
):89
–93
. .20.
Wang
Z
, Till
B
, Gao
Q
. Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells
. Oncoimmunology
. 2017
;6
(7
):e1331807
. .21.
Müller
L
, Aigner
P
, Stoiber
D
. Type I interferons and natural killer cell regulation in cancer
. Front Immunol
. 2017
;8
:304
. .22.
Braybrooke
JP
, Propper
DJ
, O'Byrne
KJ
, Koukourakis
MI
, Patterson
AV
, Houlbrook
S
, et al. Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha
. Br J Cancer
. 2000
;83
(2
):219
–24
. .23.
Terawaki
S
, Chikuma
S
, Shibayama
S
, Hayashi
T
, Yoshida
T
, Okazaki
T
, et al. IFN-α directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity
. J Immunol
. 2011
;186
(5
):2772
–9
. .24.
Eisenhauer
EA
, Therasse
P
, Bogaerts
J
, Schwartz LH
, Sargent D
, Ford R
, et al. New response evaluation criteria in solid tumours; revised RECIST guideline (version 1.1)
. Eur J Cancer
. 2009
;45
(2
):228
–47
. 25.
Mavros
MN
, Mayo
SC
, Hyder
O
, Pawlik
TM
. A systematic review: treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma
. J Am Coll Surg
. 2012
;215
(6
):820
–30
. .© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
